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ABSTRACT
Estimating the value of medical innovation is a continual challenge.  In this research, we quantify
the impact of antihypertensive therapy on U.S. blood pressures, risk and number of heart attacks,
strokes, and deaths.  We also consider the potential for further improvements.   We estimate the
value  of  innovation  using  equations  relating  blood  pressure  to  adverse  outcomes  from  the
Framingham Heart Study.   Our results show that without antihypertensive therapy, 1999-2000
average blood pressure for the U.S. population age 40 plus would have been 10-13 percent higher.
86,000 excess premature deaths from cardiovascular disease (2001), and 833,000 hospital discharges
for stroke and heart attacks (2002) would have occurred.   Life expectancy would be 0.5 (men) and
0.4 (women) years lower.  At guideline care, there would have been 89,000 fewer premature deaths
(2001) and 420,000 fewer hospital discharges for stroke and heart attack (2002) than observed.  Our
analysis suggests that antihypertensive therapy has had a significant impact on cardiovascular health
outcomes but that mortality gains would have been approximately twice as high if guideline care had
been achieved for all.
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 Hypertension is an established risk factor for conditions including coronary heart 
disease (CHD), myocardial infarction (MI), and stroke.  Over 50 million adults were 
hypertensive in 1999-2000, including 43 percent of adults age 40 and over (i.e., had Stage 
I or II blood pressures, or reported taking antihypertensive medicine).  The risk of 
developing hypertension increases with age; lifetime risk is estimated at approximately 
90 percent for individuals with normal blood pressures at age 55 or 65 and who survive to 
age 80 to 85.1  The economic burden of CHD and stroke is substantial.  Applying the 
methodologies of Rice et al. and Hodgson and Cohen to 2002 data, the total economic 
burden of CHD and stroke is estimated at $120.6 and $48.9 billion, respectively.2,3   
Drug therapy for hypertension has improved over the past four decades.  Only 
limited drug therapy existed in the late 1950s and early 1960s; the only FDA-approved 
drug therapies for hypertension were vasodilators (approved in 1946), peripherally acting 
agents (1953) and diuretics (1958).
4   Most patients who would be treated immediately 
today with effective drug therapy were untreated, or treated less effectively.  For 
example, while Harrison’s Principles of Internal Medicine (1962) found that diastolic 
blood pressure was important in determining mortality, it justified treatment only in 
properly selected cases, stating, “A woman who has tolerated her diastolic pressure of 
120 for 10 years without symptoms or deterioration does not need specific treatment for 
hypertension.”
5  As late as 1971-75, only nine percent of the population age 40 and over 
with hypertension reported in NHANES taking medication for it, and blood pressures 
were  poorly controlled; 79 percent of this treated group still had Stage I or II blood 
pressures.  Thus, the earlier time period could be called “drug-naïve” with regard to 
widespread use of a range of effective drug therapies.  5 
Over time, additional antihypertensive drugs became available – calcium channel 
blockers and beta blockers (1970s and 1980s), and ACE inhibitors and angiotensin 
receptor antagonists (1980s and 1990s).  In 1999-2000, we calculate that 61 percent of 
the population age 40 and over with hypertension reported in NHANES taking 
medication. 
  Our objective is to estimate the actual impact of antihypertensive therapy on the 
U.S. population over the past four decades and identify potential further improvements if 
guideline care were achieved.  Despite documented major strides in cardiovascular 
disease management, there has been no systematic estimate of the total impact of 
antihypertensive therapy on health outcomes. We use national survey data to estimate the 
impact of drug treatment on average blood pressures, and the best-available published 
risk equations to estimate the impact on the risk and number of MI, strokes, and deaths.  
Because the objective is to estimate the “real world” impact of antihypertensive therapy 
on outcomes for the entire population, representative national survey data were used, 





We use data on 5,046 individuals age 30-79 from the 1959-62 National Health 
Examination Survey (NHES) and 2,284 individuals age 40-79 from the 1999-2000 
National Health and Nutrition Examination Survey (NHANES); U.S. life expectancy 
tables from the National Center for Health Statistics (NCHS); hospital discharge figures 
from the National Hospital Discharge Survey (NHDS); and published risk equations from 
the Framingham Heart Study.  All observations from NHES and NHANES populated 
with the required data were included in calculations, which were performed using SAS, 
release 9.1. 
 
Statistical Analysis   
 
Determinants of hypertension, including body mass index (BMI), diabetes, family 
history, excessive alcohol use, high salt diet, exercise, race, age and sex were identified 
from literature searches.  Data on BMI, diabetes, race, age and sex were used to model 
observed blood pressure among a drug-naïve sample (the 1959-62 NHES sample). 
  The relationship between blood pressure (BP) and these explanatory factors was 
estimated using ordinary least squares (OLS) regression, with separate equations for 
systolic and diastolic blood pressure, and for men and women. 
 7 
The explanatory variables are race (BLACK, OTHER, with white being the omitted 
category), AGE (nine variables corresponding to five-year cohorts beginning with age 35, 
age 30-34 being the omitted category), BMI, BMI
2 (to account for possible non-
linearities in the effect of BMI on BP), and DIABETES (either reporting taking insulin or 
having a blood glucose level>140 mg/dL)  DIABETES, BMI, and BMI
2 terms control for 
the impact of secular population changes in the levels of diabetes and obesity. 
  To predict BP in the absence of antihypertensive drug therapy, the estimated 
structural relationship based on data from 1959-62 is applied to observed values of the 
explanatory variables for individuals in the 1999-2000 NHANES sample.  Following 
JNC-V definitions, predicted and observed systolic (SBP) and diastolic (DBP) BPs for 
each individual are assigned to five categories: Optimal, Normal, High Normal, Stage I 
and Stage II Hypertension.
6   The resulting distribution of predicted BPs for 1999-2000 is 
compared to the distribution of observed BPs.  Controlling for other identified risk factors 
for which data are available, the difference between the two distributions is attributed to 
antihypertensive therapy.  Two risk factors – sodium intake and exercise – could not be 
included in the predictive model because data are available only for 1999-2000.  A 
sensitivity analysis of the impact of these variables on BP, using 1999-2000 data, was 
conducted.  
  The impact of antihypertensive therapy on risk of death and total deaths from 
CHD is estimated using Framingham Heart Study risk equations estimated by Wilson et 
al.
7, together with NCHS population life tables and cause of death statistics.  The impact 
of antihypertensive therapy on risk of stroke and MI, and hospital discharges for stroke 8 
and MI is estimated using Framingham Heart Study risk equations estimated by 
Anderson et al.
8, and NHDS hospital discharge statistics. 
  The Wilson et al. risk equations are generated from a hazard model predicting the 
probability of a CHD event (angina, MI, or death from CHD) within the next 10 years, 
and include variables for age, total cholesterol, HDL-C, BP, diabetes and smoking.  
These equations are applied to each individual in the NHANES sample based on the 
individual’s observed characteristics.  For each individual, the probability of a CHD 
event within 10 years is calculated based on (1) observed BP and (2) predicted BP in the 
absence of antihypertensive therapy, and a relative risk ratio calculated by dividing the 
two.  The calculated relative risks are averaged across individuals within each sex-age 
cohort, according to sample population weights.  Since the variable of interest is death 
from major cardiovascular disease, average risks are combined with the probabilities for 
men and women of a given age, n, surviving to age n+1 (from the NCHS life tables),
9 and 
with the share of deaths due to major cardiovascular disease (ICD/10 I00-I78) by sex-age 
cohort (from NCHS cause of death tables by sex and age).
10  By adjusting for the share of 
total mortality due to death from major cardiovascular disease, increases in the risk of a 
CHD event in the next 10 years are assumed to increase the risk of death from major 
cardiovascular disease in the next 10 years proportionally.  Improvement in life 
expectancy attributable to antihypertensive therapy is calculated as the difference 
between life expectancy at birth reported by NCHS (with observed BPs) and calculated 
with predicted BPs.  Predicted life expectancy is derived by adjusting the risk of death in 
each year for men and women age 40 and above by the relative risk described for the 
corresponding sex-age cohort, and summing over all ages. 9 
  The Anderson et al. risk equations are generated from separate parametric models 
predicting the probability of stroke and MI for men and women of given characteristics 
(age, BP, smoking, ratio of total cholesterol to HDL-C, diabetes and ECG-LVH) over the 
next 4 to 12 years.  The recommended specification incorporating SBP is used.  For each 
individual, the risk of stroke and MI, respectively, in the next five years is calculated 
based on (1) observed BP and (2) predicted BP in the absence of antihypertensive 
therapy, and a relative risk ratio calculated by dividing the two.  The number of avoided 
hospital discharges is calculated by applying the relative risk ratio to hospital discharge 
statistics for stroke (ICD/9 430-438) and MI (ICD/9 410) by sex and age from the NHDS 
for 2002.  These risk equations allow us to isolate the effect of BP from other factors such 
as secular changes in serum cholesterol levels, diabetes rates and smoking, which also 
affect CHD risk.10 
RESULTS 
 
Predictive Structural Model of Untreated Blood Pressure 
 
OLS multivariate regression relating SBP and DBP to risk factors was used with a sample 
of 2,382 men and 2,664 women age 30-79 from the 1959-62 NHES.  Results appear in 




  Figure 1 is derived by applying the structural relationship from the untreated BP 
model for men and women, respectively, to observed characteristics of individuals in the 
1999-2000 NHANES sample.  The predicted SBPs and DBPs without antihypertensive 
drug therapy and observed BPs for each individual are assigned to five categories: 
Optimal, Normal, High Normal, Stage I and Stage II Hypertension. If an individual’s 
predicted systolic and diastolic BPs are in different categories, the more hypertensive 
category is assigned.     
 
Figure 1  
 
  For example, observed BPs for men age 40-49, treated or not, were: 36 percent 
Optimal, 26 percent Normal, 21 percent High Normal, 14 percent Stage I and 3 percent 
Stage II Hypertensive.  For the same cohort, predicted BPs without treatment were: 22 11 
percent Optimal, 22 percent Normal, 19 percent High Normal, 27 percent Stage I and 10 
percent Stage II Hypertensive.   
  Calculating weighted average BPs for each sample, we find that in the absence of 
antihypertensive drug therapy, average BPs for the population over 40 would be 10-13 
percent higher (10.0 to 10.7 percent for men and 10.4 to 12.9 percent for women for SBP 
and DBP, respectively).  Women age 70-79 exhibited the greatest difference between 
predicted and observed BPs, with 61 percent predicted and 29 percent observed with 
Stage II hypertension, compared to 41 and 12 percent, respectively, for men age 70-79.  
However, these women also experienced rates of Stage II hypertension 2.5 times higher 
than their male counterparts. 
 
Statistical Sensitivity Analyses 
 
To allow for nonlinearities, the continuous BMI variables in the BP prediction equation 
were replaced by six categories from the literature:  “less than or within normal BMI 
range”, “marginally overweight”, “overweight”, “very overweight”, “severely obese”, 
and “morbidly/super obese”.
11  The relationship between BP and BMI is linear for 
women and weakly concave for men. 
  Variables measuring reported sodium intake and exercise habits (available only 
for 1999-2000) were also included in the model.  Both have been identified as 
hypertension risk factors in the literature.  Neither increased the explanatory power of the 
model significantly; the predicted BP distributions were nearly identical with or without 
these variables.  Variables for sodium intake were never statistically significant and often 12 
had incorrect signs, while the exercise variable was occasionally significant.  They had 
no significant impact on BMI or BMI
2coefficients, and increased the R
2 measure only at 
the third decimal point.  To assess possible non-normality in the model’s error terms, a 
log-transformation of the dependent variable was regressed on the same variables.  This 
specification did not increase the model’s explanatory power nor the precision of the 
estimated coefficients significantly.   
 
Impact of Blood Pressure on Life Expectancy and Total Deaths from Major 
Cardiovascular Disease 
 
Applying the Wilson et al. risk equation for CHD events within the next 10 years to each 
individual in the 1999-2000 sample, and averaging the effect over the entire population, 
the total increase in life expectancy associated with antihypertensive drug therapy is 0.5 
years (men) 0.4 years (women).  Averaged over only the population with predicted Stage 
I or Stage II hypertension, the values are 0.9 years (men) and 0.6 years (women).  
Applying the change in risk of death to total deaths for each sex-age cohort, an estimated 
86,000 excess premature deaths from cardiovascular disease (50,000 men, 36,000 
women) would have occurred in 2001 among the U.S. population age 40 plus in the 
absence of antihypertensive drug therapy.  For adults age 40 plus, observed 2001 total 
deaths and deaths from major cardiovascular disease are four and nine percent lower, 
respectively, than predicted levels with untreated BPs.  Due to potential competitive 
mortality, these estimates represent reductions in premature deaths due to cardiovascular 
disease; reductions in total mortality from all causes in a given year may be lower. 13 
If all patients with Stage I or Stage II hypertension who reported being untreated 
had been treated, as recommended in JNC 7
12(p 1211), and all treated patients achieved 
normal BPs, we calculate an additional 89,000 fewer premature deaths from major 
cardiovascular disease in 2001 than actually occurred.  This is likely an underestimate 
because it assumes that those dying are no more likely to have high BP than the general 
population. 
 
Impact of Blood Pressure on MI and Stroke 
 
Similarly, for each individual in the NHANES 1999-2000 sample, we calculate the 
separate risks of stroke or MI within the next five years, applying the Anderson et al. 
equations.  In the absence of antihypertensive drug therapy, there would have been 
572,000 more hospital discharges for stroke in 2002 (162,000 men, 410,000 women), and 
261,000 more discharges for MI (87,000 men, 174,000 women).  This is a 38 percent 
reduction in discharges for stroke and a 25 percent reduction for MI, compared to 
predictions with untreated BPs.  Most of this improvement represents stroke and MI 
avoided altogether, rather than delayed.  Even if all the predicted reduction in discharges 
were for patients with predicted Stage II hypertension (those most likely to have a stroke 
in the future), we calculate only seven percent of discharges for stroke and five percent 
for MI would have occurred in the future; the remainder were avoided altogether.    
We also calculate considerable improvements if guideline care were achieved.  If 
all untreated patients with Stage I or Stage II hypertension had been treated, and all 
treated patients achieved normal BPs, there would have been an additional 278,000 14 
(stroke) and 142,000 (MI) fewer hospital discharges in 2002 than actually occurred.  This 
is likely an underestimate because it assumes that those discharged for stroke and MI are 
no more likely to have high BP than the general population. 
 
Table 2 15 
DISCUSSION 
 
  By many measures, hypertension is much better treated now than in the past.  
Although further efforts are still needed to bring health benefits to all, awareness, 
treatment, and control of hypertension have shown considerable improvement since 
NHANES II (1976-80)
12(p 1207).  The estimated impact of antihypertensive therapy on BP 
is substantial: approximately 10 percent (SBP) and 13 percent (DBP) for both men and 
women age 40 plus, compared to predicted untreated BP.  Better-controlled BP translated 
into nine percent fewer deaths from major cardiovascular disease in 2001, and 38 percent 
and 25 percent fewer hospital discharges for stroke and MI in 2002, respectively, 
compared to predicted levels in the absence of drug therapy.   Placing the estimated 
reduction of approximately 86,000 deaths in context, U.S. deaths from motor vehicle 





This study quantifies the impact of antihypertensive drugs in terms of avoided 
premature deaths from cardiovascular disease and excess hospitalizations for stroke and 
MI.  Assigning a monetary value to these outcomes and drawing on figures from the 
literature for 1998, we calculate a benefit-cost ratio of over 12:1 for men and 11:1 for 
women by comparing life expectancy benefits to antihypertensive drug expenditures. We 
assume each year of additional life in good health is valued at $90,000 (a generally 
accepted value of $100,000, less $10,000 in average support costs during non-working 
years paid by government),
14 and expenditures on antihypertensive drugs average $2,600 16 
for men (over a 73.8-year expected lifespan) and $3,248 for women (over a 79.5-year 
expected lifespan).
15  We discount both costs and benefits at three percent a year, the 
inflation-adjusted U.S. Treasury bond yield. 
  Previous studies have concluded that antihypertensive treatment is cost-effective; 
Weinstein reports estimates of the number of quality-adjusted life years achieved with 
each $1 million spent on antihypertensive drug therapy as between 20-50 
(antihypertensive treatment, DBP 95-104) to more than 200 (beta-blockade post-
myocardial infarction, high risk).  As a benchmark, $1 million spent for dialysis for end-
stage renal disease is estimated to yield 10-20 quality-adjusted life years.
16   
Reduced hospitalizations for stroke and MI increase calculated net benefits 
further.  Dividing figures from the literature for total hospital costs for CHD and 
cerebrovascular disease
17, 18 by corresponding hospital discharges, and assuming hospital 
costs represent 70 percent of direct medical costs in the year following stroke and MI,
19 
we estimate 2002 total direct medical costs avoided due to fewer strokes and MI of $10.7 
billion and $5.8 billion, respectively.  Including the impact of antihypertensive drugs on 
quality of life and work productivity would increase the benefit–cost ratio further.   
While the benefits have been substantial, significant opportunities remain to 
extend drug treatment to more who could benefit.  We estimate life expectancy could 
increase an additional 0.3 years (men) and 0.1 years (women) if therapy were extended to 
all with Stage I or Stage II hypertension not currently treated with medication, and an 
additional 0.2 years for both men and women if those treated achieved normal BP.  These 
figures translate into an additional 89,000 avoided premature deaths from major 17 
cardiovascular disease, and an additional 278,000 (stroke) and 142,000 (MI) avoided 





The methodology used is a residual analysis.  It controls for all risk factors for which data 
are available, and confirms that omitted sodium and exercise variables are unlikely to 
have a significant impact.  There remains, however, the possibility that unknown factors 
may have contributed to differences between observed and predicted BPs.  In particular, 
some researchers suggest a downward cohort effect due to unknown, population-level 




levels of observed BP by age were lower for more recent birth cohorts.  However, 
because observed BPs include both treated and untreated BPs, the observed cohort effect 
is confounded by the impact of treatment.  Even in lowest-decile SBPs, where 
“pharmacologic management is unlikely to have had any impact,”
20 1999-2000 NHANES 
data show nine percent age 40 plus reported taking hypertension medication (increasing 
to 29 percent age 60 plus).  We adjust for this confounding treatment effect by calculating 
the ratio of untreated to all lowest-decile SBPs in the 1999-2000 sample (by age), and 
adjusting the authors’ estimates thereby. Assuming the improvement in the lowest decile, 
as adjusted, to be entirely due to a cohort effect would reduce our estimate of the impact 
of BP improvements modestly, from a nine- to an eight-percent reduction in 2001 
premature deaths from cardiovascular disease.  18 
 Our calculations assume the 1959-62 data provide a reliable predictive basis for 
calculating the structural relationship between BP and explanatory variables, notably 
BMI and  BMI
2, and that the sample is  “drug-naïve.”  While NHANES data are available 
for subsequent time periods (1971-75, 1976-80, 1988-94, and 1999-2000), their 
suitability for estimating this relationship is compromised by the increasing proportion 
being treated with antihypertensive drugs, thereby rendering the remaining untreated 
population increasingly unrepresentative.  When similar equations are estimated in later 
years with only the remaining untreated individuals, the predicted impact of a change in 
BMI (and BMI
2) on BP was always positive, but generally became smaller over time, 
consistent with an increasingly selective untreated population.  While treatment rates 
were low in 1959-62 and few effective clinical options were available, to the degree that 
some individuals were treated effectively, predicted untreated BPs for 1999-2000, and 
therefore the estimated impact of treatment on mortality and morbidity, would be 
understated.  The study design may also overestimate strokes and MI avoided due to a 
“survival bias”; specifically, in the absence of effective BP control, the total population 
with hypertension would have been smaller and some individuals who had a stroke or MI 
in 2002 would have died previously.  However, there is a likely countervailing 
underestimation effect, in that those discharged for stroke and MI are assumed to be no 
more likely to have high BP than the general population.  The net impact of these effects 
is unknown. 
Finally, the study design relies on Framingham Heart Study risk equations.  To 
the degree that these equations were estimated on an essentially all-white population, and 
that cardiovascular risk for the same level of BP may be higher for non-white 19 
populations, all other factors held constant, we have underestimated the impact of 
treatment. 20 
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Tables and Figures 
 
Table 1.  Structural Model of Untreated Systolic and Diastolic Blood Pressure for Men 
and Women ages 30 to 79 
 
 











Black 7.605 * 1.327 8.114 * 1.341 5.662 * 0.790 5.631 * 0.741
Other -5.246 *** 3.043 -13.337 * 3.683 0.190 1.811 -3.367 *** 2.036
Age 35-39 0.139 1.489 0.958 1.536 1.330 0.886 1.233 0.849
Age 40-44 2.371 1.470 6.577 * 1.589 3.348 * 0.875 3.940 * 0.879
Age 45-49 4.641 * 1.503 10.912 * 1.587 4.599 * 0.894 5.223 * 0.877
Age 50-54 8.139 * 1.560 15.185 * 1.689 4.886 * 0.929 5.870 * 0.934
Age 55-59 11.501 * 1.635 21.105 * 1.717 5.063 * 0.973 7.149 * 0.949
Age 60-64 15.238 * 1.688 27.409 * 1.833 5.017 * 1.005 7.817 * 1.013
Age 65-69 19.443 * 1.816 34.495 * 1.842 3.680 * 1.081 7.742 * 1.018
Age 70-74 24.767 * 2.014 42.432 * 2.020 3.289 * 1.199 4.821 * 1.117
Age 75+ 29.205 * 2.344 36.163 * 2.495 2.715 ** 1.395 3.157 ** 1.379
BMI 2.567 * 0.806 1.722 * 0.551 2.007 * 0.480 1.295 * 0.305
BMI 2 -0.025 *** 0.015 -0.006 0.010 -0.021 ** 0.009 -0.008 0.005




Note: * indicates significance at the 1% level; ** at the 5% level; *** at the 10% level.
Systolic Blood Pressure Diastolic Blood Pressure
Variable











Table 2:  Predicted Achieved and Potential Further Improvements in Life Expectancy 
and Deaths Avoided, 2001, and Hospital Discharges for MI and Stroke Avoided, 2002, 






























TOTAL 910,126 86,098 89,150 915,022 571,930 278,160 794,080 260,701 142,696
MALE 420,330 49,884 49,951 417,415 161,994 122,527 461,245 86,866 67,312
.40 to 44 years 7,508 937 845 8,991 4,336 621 26,079 7,395 1,110
1.017 , 1.037 1.400 , 1.565 1.207 , 1.361
.45 to 49 years 12,418 1,270 1,145 19,011 5,923 2,148 27,741 4,954 1,793
1.017 , 1.037 1.235 , 1.388 1.126 , 1.231
.50 to 54 years 18,442 3,261 2,324 23,094 5,388 5,101 45,416 4,697 6,171
1.038 , 1.073 1.171 , 1.295 1.070 , 1.137
.55 to 59 years 22,489 3,689 2,629 32,509 10,870 6,929 55,019 9,142 6,453
1.038 , 1.073 1.255 , 1.414 1.116 , 1.217
.60 to 64 years 27,831 5,067 4,266 45,942 23,517 10,925 49,159 12,003 6,407
1.051 , 1.077 1.434 , 1.589 1.204 , 1.285
.65 to 69 years 36,221 6,506 5,478 48,040 18,161 15,124 56,299 10,508 8,880
1.051 , 1.077 1.316 , 1.440 1.155 , 1.218
.70 to 74 years 51,535 5,855 6,681 66,281 25,923 22,573 53,954 10,218 9,771
1.032 , 1.053 1.318 , 1.464 1.151 , 1.228
.75 years and over 243,886 23,299 26,584 173,547 67,875 59,105 147,578 27,949 26,727
1.032 , 1.053 1.318 , 1.464 1.151 , 1.228
Improvement in Life Expectancy 0.5 0.5
FEMALE 489,796 36,214 39,199 497,607 409,936 155,632 332,835 173,835 75,384
.40 to 44 years 3,610 979 213 7,795 5,184 402 7,638 4,838 344
1.035 , 1.061 1.565 , 1.765 1.412 , 1.855
.45 to 49 years 5,350 1,308 284 16,598 11,128 1,451 11,502 6,918 910
1.035 , 1.061 1.556 , 1.785 1.425 , 1.778
.50 to 54 years 8,240 1,514 842 28,323 11,943 5,514 13,905 4,487 2,061
1.026 , 1.057 1.337 , 1.506 1.231 , 1.415
.55 to 59 years 10,846 1,837 1,022 26,132 16,582 5,155 29,537 13,165 4,139
1.026 , 1.057 1.523 , 1.746 1.323 , 1.569
.60 to 64 years 15,058 4,009 2,387 37,766 24,938 9,855 26,852 10,844 4,930
1.057 , 1.088 1.545 , 1.776 1.312 , 1.496
.65 to 69 years 22,845 5,479 3,262 42,976 35,389 12,373 36,247 19,081 7,219
1.057 , 1.088 1.695 , 1.952 1.407 , 1.645
.70 to 74 years 37,808 2,607 3,856 64,382 58,050 23,024 34,794 19,232 9,369
1.016 , 1.030 1.771 , 2.032 1.448 , 1.658
.75 years and over 386,039 18,482 27,332 273,635 246,722 97,858 172,360 95,270 46,411
1.016 , 1.030 1.771 , 2.032 1.448 , 1.658
Improvement in Life Expectancy 0.4 0.3
* 95% confidence interval.
**Antihypertensive Therapy.
Sources:
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Relative Risk of 
CHD Event *
1.027
Deaths from Major Cardiovascular Disease, 2001
 25 
Figure 1:  Predicted and Observed Blood Pressure, Men, 1999-2000  
 















































Predicted Observed Predicted Observed Predicted Observed Predicted Observed
40-49 50-59 60-69 70-79















































Predicted Observed Predicted Observed Predicted Observed Predicted Observed
40-49 50-59 60-69 70-79
Optimal Normal High Normal Stage I Hypertension Stage II Hypertension
Optimal: SBP<120, DBP< 80; Normal: SBP 120-129, DBP 80-84; High Normal: SBP 130-139, DBP 85-89;  
Stage I: SBP 140-159, DBP 90-99; Stage II Hypertension: SBP>=160, DBP>=100 26 
Figure 2:  Predicted and Observed Deaths, 2001, and Hospital Discharges for Stroke and 




































































































































































































































Deaths from Major Cardiovascular Disease,
2001
Hospital Discharges for Stroke, 2002 Hospital Discharges for MI, 2002
Total
Male
Female